Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Castration resistant prostate cancer (CRPC) is responsive to androgen receptor (AR) axis
targeted agents; however, patients invariably relapse with resistant disease that often …

Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective
targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant …

The oncogenic MUC1-C protein drives dedifferentiation of castrate resistant prostate cancer
(CRPC) cells in association with chromatin remodeling. The present work demonstrates that …

Background and purpose Positive surgical margins (PSMs) correlate with adverse outcomes
in numerous solid tumours. However, the prognostic value of PSMs in prostate cancer (PCa) …

Prostate cancer remains the most common non-cutaneous malignancy among men in the
United States. To discover potential serum-based biomarkers for high-risk prostate cancer …

The assessment of the risk of biochemical recurrence (BCR) is critical in the management of
males with prostate cancer (PC). Over the past decades, a comprehensive effort has been …

Twenty mucin genes have been identified and classified in two groups (encoding secreted
and membrane-bound proteins). Secreted mucins participate in mucus formation by …

Sialic acids have been implicated in cancer initiation, progression, and immune evasion in
diverse human malignancies. Sialylation of terminal glycans on cell surface and secreted …

Targeted clearance of colorectal cancer stem cells (CCSCs) has become a novel strategy for
tumor immunotherapy. Molecule mucin1 (MUC1) is one of targetable cell surface antigens in …